NYSE:BHVN
Biohaven Pharmaceutical Holding Co Ltd Stock News
$33.68
-0.495 (-1.45%)
At Close: Jul 03, 2024
The 3 Smartest Healthcare Stocks to Buy With $1K Right Now
10:00am, Friday, 28'th Jun 2024
Healthcare stocks to buy have been off to the races recently — especially the ones in the weight-loss drug market. Indeed, the market is huge and could entail considerable growth for many years into
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
09:12am, Wednesday, 29'th May 2024
Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE™) platform BHV-1300 de
-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the pote
Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
03:10am, Saturday, 18'th May 2024
Biohaven Ltd. is a spinout of Biohaven Pharmaceutical, focusing on developing drugs in the life sciences field. BHVN has three Phase 3 drug candidates: troriluzole for OCD, taldefgrobep alfa for SMA,
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
10:35am, Tuesday, 14'th May 2024
Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
10:36am, Monday, 13'th May 2024
The heavy selling pressure might have exhausted for Biohaven Ltd. (BHVN) as it is technically in oversold territory now.
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
04:05pm, Thursday, 09'th May 2024
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net proceeds of approximately $247.8 million from Biohaven'
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar
02:38pm, Wednesday, 01'st May 2024
Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treat
These Biotechs and IPOs Inspire Big Insider Buying
08:15am, Sunday, 28'th Apr 2024
As tech giants and other sector leaders report their most recent quarterly results, one might expect notable insider purchases to be scarce.
3 Biotech Stocks to Buy on the Dip: April 2024
06:00am, Friday, 26'th Apr 2024
If you follow Warren Buffett's advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis centers on the underlyin
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
04:05pm, Monday, 22'nd Apr 2024
NEW HAVEN, Conn. , April 22, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
06:00am, Thursday, 18'th Apr 2024
NEW HAVEN, Conn. , April 18, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Proposed Public Offering of Common Shares
04:05pm, Wednesday, 17'th Apr 2024
NEW HAVEN, Conn. , April 17, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechani
